Omar Khalil

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

Kestrel Therapeutics, Inc. operates as a biotechnology development company. The company is based in Wayland, MA. The CEO of the company is Frank G. Haluska.

MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer.

Kestrel Therapeutics, Inc. operates as a biotechnology development company. The company is based in Wayland, MA. The CEO of the company is Frank G. Haluska.

MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer.

MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer.

MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Kestrel Therapeutics, Inc. operates as a biotechnology development company. The company is based in Wayland, MA. The CEO of the company is Frank G. Haluska.

MycRx is an Australian company that focuses on improving the lives of people with cancer through direct myc inhibitors. The company's main area of expertise is the science of myc inhibition as a treatment for cancer.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.